A definitive reference covering stereochemical science, the 1992 FDA policy and its commercial aftershocks, chiral separation technology roadmaps, Forest Labs […]

How to read the FDA’s most underused signal, map the Hatch-Waxman timeline with precision, and turn patent intelligence into a

1. Why the PTAB Is the Single Most Important Variable in Pharmaceutical Patent Valuation Analysts who model pharmaceutical patent portfolios

The revenue locked inside a single patent grant can exceed the GDP of a small country. AbbVie’s Humira franchise generated

1. What Patent Opposition Actually Is, and What It Costs A patent opposition is a formal administrative procedure at a

The pharmaceutical patent cliff narrative has dominated investor and analyst conversations for two decades, but it increasingly misses the point

What Nonprofit Pharma Actually Is (And Isn’t) Understanding the Structural Distinction ‘Nonprofit pharma’ covers at least three distinct entity types,

1. The Economics Driving the Biosimilar IP War The global biosimilar market is not a niche regulatory experiment. It is